TRIACORT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TRIACORT (TRIACORT).
Adrenocorticosteroid; binds to glucocorticoid receptor, modulating gene expression to produce anti-inflammatory, immunosuppressive, and metabolic effects.
| Metabolism | Hepatic via CYP3A4; metabolites are inactive. |
| Excretion | Primarily hepatic metabolism (>90%) with renal excretion of inactive metabolites (approximately 80% in urine, 20% in feces). Less than 5% of the parent drug is excreted unchanged in urine. |
| Half-life | 2-3 h. The terminal elimination half-life is short, requiring thrice-daily dosing for sustained effect. Context: In patients with hepatic impairment, half-life may be prolonged up to 4-5 h. |
| Protein binding | Approximately 78% bound to corticosteroid-binding globulin (CBG) and albumin. Binding is saturable at higher concentrations. |
| Volume of Distribution | 1.4 ± 0.5 L/kg. This large Vd indicates extensive extravascular distribution, reflecting high tissue penetration and sequestration in adipose tissue. |
| Bioavailability | Oral: 80-90% (well-absorbed with minimal first-pass metabolism); Intramuscular: 100% (assuming correct administration). |
| Onset of Action | Oral: 30-60 min; Intramuscular: 1-2 h; Intravenous: immediate (minutes). Onset is faster with intravenous administration due to rapid distribution. |
| Duration of Action | Single oral dose: 12-36 h; Therapeutic duration for glucocorticoid effect is 12-24 h. Clinical note: Duration is dose-dependent; higher doses provide longer duration but increase side effects. |
| Molecular Weight | 348.4 Da (for triamcinolone, assuming TRIACORT is triamcinolone) |
| Action Class | Glucocorticoids |
| Brand Substitutes | Torsinol Injection, Catram 40mg Injection, Avcort 40mg Injection, Amecort Injection, Sterochem-T Injection |
10-20 mg orally once daily
| Dosage form | CREAM |
| Renal impairment | No adjustment required for GFR >30 mL/min; for GFR 10-30 mL/min, reduce dose by 50%; for GFR <10 mL/min, avoid use |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use |
| Pediatric use | 0.5-1 mg/kg orally once daily, max 20 mg/day |
| Geriatric use | Initiate at 5 mg orally once daily; titrate cautiously due to increased risk of adverse effects |
| 1st trimester | Corticosteroids like TRIACORT are associated with a small increased risk of oral clefts. Use only if clearly needed. |
| 2nd trimester | Possible fetal growth restriction with prolonged use. Use lowest effective dose. |
| 3rd trimester | May cause neonatal adrenal suppression. Monitor infant after birth. |
Clinical note
Comprehensive clinical and safety monograph for TRIACORT (TRIACORT).
| Placental transfer | Placental transfer occurs; metabolized by placental 11β-HSD2 but some active drug reaches fetus. |
| Breastfeeding | TRIACORT is excreted into breast milk in small amounts, but at maternal doses up to 20 mg/day, it is unlikely to affect the infant. Monitor for growth and adrenal suppression. |
| Lactation Rating |
■ FDA Black Box Warning
Corticosteroids may cause immunosuppression, increasing susceptibility to infections. Avoid live vaccines in patients on high-dose therapy.
| Serious Effects |
Systemic fungal infectionHypersensitivity to triamcinolone or any component
| Precautions | Immunosuppression and increased infection risk, Adrenal suppression with prolonged use, Osteoporosis risk with long-term use, Growth suppression in children, Cushing's syndrome with prolonged use, Exacerbation of fungal infections |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing TRIACORT levels. Limit high-sodium foods to reduce fluid retention. Maintain adequate potassium intake (bananas, oranges, spinach) to counteract hypokalemia. Alcohol may increase gastric irritation. |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: associated with increased risk of cleft palate (odds ratio ~3.4). Second/third trimester: increased risk of intrauterine growth restriction, oligohydramnios, and fetal adrenal suppression. Chronic use may cause neonatal adrenal insufficiency. Human data limited; animal studies show teratogenicity. |
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose (glucose intolerance), and signs of infection. Serial fetal ultrasound for growth restriction and amniotic fluid volume. Neonatal monitoring for adrenal suppression (hypoglycemia, hypotonia) after delivery. |
| Fertility Effects | May impair fertility in both sexes. In females: disruption of menstrual cycle and ovulation. In males: decreased sperm motility and concentration. Effects are dose- and duration-dependent; usually reversible upon discontinuation. |
| Clinical Pearls | TRIACORT is a synthetic corticosteroid with high glucocorticoid potency and minimal mineralocorticoid activity. It has a long duration of action (36-54 hours) allowing once-daily dosing. Monitor for adrenal suppression during taper; dexamethasone suppression test may require extended sampling. Use cautiously in patients with diabetes, osteoporosis, or peptic ulcer disease. Intra-articular injection can cause post-injection flare; avoid in infected joints. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly or adjust dose without consulting your doctor. · Report any signs of infection (fever, sore throat, cough) or unusual bleeding/bruising immediately. · Avoid live vaccines while taking this medication. · Monitor blood glucose closely if you have diabetes. · Carry a medical alert card indicating you are taking corticosteroids. · Do not take NSAIDs or aspirin without medical advice due to increased GI bleeding risk. · Notify your doctor if you experience vision changes, severe headache, or mood disturbances. |